Avecia Biotechnology, Inc.

Paul McCormac

Andrew Guy Livingston

Andrew Timothy Boam

Donald Alfred Wellings

David John Moody

Stephen Hargreaves

Dinesh Nair

A process for the purification of an oligonucleotide synthon is provided. The process comprises subjecting an organic solution comprising an oligonucleotide synthon and lower molecular weight impurities to nanofiltration whereby the ratio of an oligonucleotide synthon to lower molecular weight impurities in the solution is increased after the nanofiltration. Preferably, the oligonucleotide synthon is a nucleoside phosphoramidite or nucleoside H-phosphonate. The nanofiltration membrane is preferably a polyimide membrane having a molecular weight cut off of 400.

Process for purifying oligonucleotide synthons

A process for the synthesis of an oligonucleotide is provided in which an oligonucleotide is assembled on a swellable solid support using the phosphoramidite approach in the presence of an activator, wherein the activator is not tetrazole or a substituted tetrazole. Preferred activators are pyridinium, imidazolinium and benzimidazolinium salts; benzotriazole and derivatives thereof; and saccharin or a saccharin derivative. Preferred swellable solid supports comprise functionalised polystyrene, partially hydrolysed polyvinylacetate or poly(acrylamide).

Process for the preparation of oligonucleotides

A process for the preparation of an oligonucleotide is provided. The process comprises the assembly of an oligonucleotide attached to a solid support, wherein the solid support is prepared by a process comprising polymerisation of a monomer which comprises a protected hydroxypolyCalkyleneoxy chain attached to a polymerisable unit wherein the protected hydroxypolyCalkyleneoxy chain contains from 2 to 10 Calkyleneoxy groups and wherein the hydroxypolyCalkyleneoxy chain is protected with an acid-labile protecting group, preferably an optionally substituted trityl group.

Growing community of inventors

Grangemouth, United Kingdom

Paul McCormac